Drugs / Lactobacillus GG
Lactobacillus GG
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01368029 | Sep 2011 → May 2012 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00934453 | Dec 2009 → May 2012 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00992290 | Oct 2009 → Dec 2012 | hepatic encephalopathy | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00895336 | Mar 2011 → Mar 2012 | ulcerative colitis | Children's Hospital Medical Center, Cincinnati | Withdrawn | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00304863 | Aug 2008 → Jul 2010 | Clostridium difficile colitis, enterocolitis | Michael E. DeBakey VA Medical Center | Withdrawn | No outcome recorded |
| Phase not applicable2 trials · 1 missed | ||||||
| — | NCT00220519 | Oct 2004 → May 2005 | — | Shriners Hospitals for Children | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00224432 | Mar 2001 → Sep 2002 | atopic eczema | Groningen Research Institute for Asthma and COPD | Completed | Missed primary |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT01782755 Comparator | Oct 2013 → Aug 2014 | Clostridium difficile colitis, diarrheal disease | McMaster University | Completed | No outcome recorded |
| Phase 4 | NCT02462590 Comparator | Jun 2015 → Mar 2019 | Clostridium difficile colitis, diarrheal disease | McMaster University | Completed | No outcome recorded |
| — | NCT04898686 Comparator | Aug 2020 → Aug 2021 | allergic disease | University Hospital, Antwerp | Completed | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus GG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00992290 ↗ |
| Known as | Culturelle | “Patients receive 1 × 1010 colony forming units of L. rhamnosus GG (Culturelle, Locin Industries Ltd) or an identical placebo suspended in tap water administered twice daily via...” NCT01782755 ↗1“L. rhamnosus GG (Culturelle, Locin Industries Ltd)” NCT02462590 ↗ |
| Known as | L. rhamnosus GG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02462590 ↗ |
| Known as | Lacticaseibacillus rhamnosus GG | “chewables containing Lacticaseibacillus rhamnosus GG” NCT04898686 ↗ |
| Known as | Lactobacillus rhamnosus GG | “The aim of the PROSPECT Pilot Trial is to determine the feasibility of performing a larger trial in mechanically ventilated critically ill patients investigating Lactobacillus...” NCT01782755 ↗ |
| Known as | Lactobacillus rhamnosus GG ATCC 53103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01368029 ↗ |
| Known as | LGG | “This proposal intends to define Lactobacillus GG (LGG) as a biologically-based alternative therapy for MHE with special focus on metabolic and stool bacteriologic changes.” NCT00992290 ↗ |
| Modality | Other / unclassified | “Lactobacillus GG, a probiotic, replenishes the healthy flora of the intestinal tract and may decrease the risk of diarrhea and infection during critical illness.” NCT00220519 ↗ |
| Route | Oral | “All supplements will be administered orally or via feeding tube.” NCT00220519 ↗ |